Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664655 | 0.91 | RAB9A (0.36) | SLC8A1RAB9ABRD4RIPK1 | |
| SCHEMBL5116463 | 0.91 | RAB9A (0.36) | SLC8A1RAB9ABRD4RIPK1 | |
| SCHEMBL5511930 | 0.90 | ATP4A (0.33) | LIPGSLC8A1RAB9A | |
| SCHEMBL4964116 | 0.89 | RAB9A (0.36) | SLC8A1RAB9ACNR1CNR2RXFP1 | |
| SCHEMBL6019450 | 0.88 | DHODH (0.36) | SLC8A1RAB9A | |
| SCHEMBL6020045 | 0.88 | DHODH (0.36) | SLC8A1RAB9A | |
| SCHEMBL4663178 | 0.88 | DHODH (0.36) | SLC8A1RAB9A | |
| SCHEMBL4666556 | 0.88 | SLC8A1 (0.43) | SLC8A1RAB9AMAPK1 | |
| SCHEMBL5506543 | 0.87 | RAB9A (0.35) | SLC8A1RAB9A | |
| SCHEMBL4666543 | 0.87 | RAB9A (0.35) | SLC8A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | claimed |
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| EP-1863820-A1 | THIOAMIDE-SUBSTITUTED TRICYCLIC BENZIMIDAZOLES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | Nycomed GmbH (DE) | 2007-12-12 | — | — | EP | disclosed |
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| WO-2006100255-A1 | THIOAMIDE-SUBSTITUTED TRICYCLIC BENZIMIDAZOLES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | NYCOMED GMBH (DE) | 2006-09-28 | — | — | WO | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1613626-A1 | CYCLIC BENZIMIDAZOLES | ALTANA Pharma AG (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087701-A1 | CYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | LIPG 4515/4885SLC8A1 3053/4885RAB9A 4475/4885 |
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | LIPG 1760/4885SLC8A1 3552/4885RAB9A 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.